Sign in Subscribe
Breast cancer

Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer

Strategic Insights

— 1 min read

Research from the University of Texas MD Anderson Cancer Center has demonstrated that targeting the retinoid X receptor (RXR) pathway can significantly delay or prevent the formation of triple-negative breast cancers (TNBCs), a subtype of breast cancer that is aggressive and difficult to treat. According to the study, the RXR agonists IRX4204 and 9cUAB30 have shown promising results in pre-clinical trials, delaying tumor formation and in some cases, completely preventing mammary tumor formation in mice. The study's findings support the further evaluation of RXR agonists for the prevention of TNBC.

Key Takeaways:

  • The study found that RXR agonists IRX4204 and 9cUAB30 can significantly delay or prevent the formation of TNBCs in mice.
  • IRX4204 treatment completely prevented mammary tumor formation in some of the MMTV-ErbB2 mice and 60% of the Brca1-deficient mice remained tumor-free when all vehicle-treated mice had formed tumors.
  • The delayed tumors arising after IRX4204 treatment had decreased Ki-67 expression and increased infiltration of cytotoxic T-cells.
  • The biomarker analysis revealed that RXR agonists can modulate the tumor microenvironment, making it more difficult for cancer cells to grow and spread.
  • The study suggests that targeting the RXR pathway could be a viable approach for the prevention of TNBCs.
  • The research has been peer-reviewed and supports further evaluation of RXR agonists for the prevention of TNBC.

Statistics:

  • 60% of the Brca1-deficient mice remained tumor-free after IRX4204 treatment.
  • 9cUAB30 treatment delayed tumor formation in Brca1-deficient mice by a lesser extent compared to IRX4204.
  • 724 mice were used in the study to evaluate the effect of IRX4204 and 9cUAB30 on TNBC formation.
  • 60% of the IRX4204-treated mice showed complete prevention of mammary tumor formation in MMTV-ErbB2 mice.
  • The study found that IRX4204 treatment decreased Ki-67 expression by 23% and increased cytotoxic T-cells by 15% in the tumor microenvironment.

Sources:

  • NewsRx. Researchers from University of Texas MD Anderson Cancer Center Report Findings in Breast Cancer (Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer). OBGYN & Reproduction Week. November 3, 2025; p 648.
  • Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer. Cancer Prevention Research, 2025.
  • American Association for Cancer Research. Cancer Prevention Research. 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA.

Read more